ANI Pharmaceuticals Announces Buyout of Royalty Obligation for ILUVIEN® and YUTIQ®
ANI Pharmaceuticals (ANIP) has announced the completion of a buyout of its 3.125% perpetual royalty obligation to SWK Funding for ILUVIEN® and YUTIQ® products. The company made a one-time payment of $17.25 million, funded through cash on hand, eliminating future royalty payments on worldwide net revenues effective January 1, 2025.
According to CEO Nikhil Lalwani, this strategic move demonstrates ANI's commitment to strengthening its Retina portfolio while enhancing financial flexibility and growth potential for these key products.
ANI Pharmaceuticals (ANIP) ha annunciato il completamento dell'acquisizione del suo obbligo di royalty perpetua del 3,125% verso SWK Funding per i prodotti ILUVIEN® e YUTIQ®. L'azienda ha effettuato un pagamento una tantum di 17,25 milioni di dollari, finanziato tramite liquidità disponibile, eliminando i pagamenti di royalty futuri sui ricavi netti mondiali a partire dal 1° gennaio 2025.
Secondo il CEO Nikhil Lalwani, questa mossa strategica dimostra l'impegno di ANI nel rafforzare il suo portafoglio Retina, migliorando al contempo la flessibilità finanziaria e il potenziale di crescita per questi prodotti chiave.
ANI Pharmaceuticals (ANIP) ha anunciado la finalización de la compra de su obligación de regalías perpetuas del 3.125% a SWK Funding por los productos ILUVIEN® y YUTIQ®. La compañía realizó un pago único de 17.25 millones de dólares, financiado a través de efectivo disponible, eliminando los pagos de regalías futuros sobre los ingresos netos mundiales a partir del 1 de enero de 2025.
Según el CEO Nikhil Lalwani, este movimiento estratégico demuestra el compromiso de ANI para fortalecer su cartera de Retina mientras mejora la flexibilidad financiera y el potencial de crecimiento de estos productos clave.
ANI Pharmaceuticals (ANIP)는 ILUVIEN® 및 YUTIQ® 제품에 대한 SWK Funding의 3.125% 영구 로열티 의무 인수 완료를 발표했습니다. 회사는 1,725만 달러의 일회성 지급을 현금으로 조달하여, 2025년 1월 1일부터 전 세계 순수익에 대한 향후 로열티 지급을 없앴습니다.
CEO Nikhil Lalwani에 따르면, 이번 전략적 결정은 ANI가 망막 포트폴리오를 강화하고 이 주요 제품들의 재정적 유연성과 성장 잠재력을 향상시키려는 의지를 보여줍니다.
ANI Pharmaceuticals (ANIP) a annoncé l'achèvement du rachat de son obligation de redevance perpétuelle de 3,125 % envers SWK Funding pour les produits ILUVIEN® et YUTIQ®. L'entreprise a effectué un paiement unique de 17,25 millions de dollars, financé par des liquidités disponibles, éliminant ainsi les paiements de redevances futurs sur les revenus nets mondiaux à compter du 1er janvier 2025.
Selon le PDG Nikhil Lalwani, ce mouvement stratégique démontre l'engagement d'ANI à renforcer son portefeuille Retina tout en améliorant la flexibilité financière et le potentiel de croissance de ces produits clés.
ANI Pharmaceuticals (ANIP) hat den Abschluss des Kaufs ihrer 3,125% perpetuellen Lizenzverpflichtung gegenüber SWK Funding für die Produkte ILUVIEN® und YUTIQ® bekannt gegeben. Das Unternehmen hat eine Einmalzahlung von 17,25 Millionen Dollar geleistet, die aus vorhandenen liquiden Mitteln finanziert wurde, wodurch zukünftige Lizenzzahlungen auf weltweite Nettoerlöse ab dem 1. Januar 2025 entfallen.
Laut CEO Nikhil Lalwani zeigt dieser strategische Schritt das Engagement von ANI, sein Retina-Portfolio zu stärken und gleichzeitig die finanzielle Flexibilität und das Wachstumspotenzial dieser Schlüsselprodukte zu verbessern.
- Elimination of 3.125% perpetual royalty obligation on ILUVIEN and YUTIQ revenues
- Increased profit margins on future sales of both products
- Enhanced financial flexibility for future growth
- Strong cash position demonstrated by ability to fund $17.25M payment with cash on hand
- Significant immediate cash outlay of $17.25 million reducing current cash reserves
BAUDETTE, Minn., March 18, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that it has completed the buyout of its
Nikhil Lalwani, President and CEO of ANI stated, “This transaction reflects our commitment to strengthening our Retina portfolio and maximizing the long-term value of ILUVIEN and YUTIQ. By eliminating this royalty obligation, we have enhanced our financial flexibility and ability to accelerate growth as we pursue our purpose of ‘Serving Patients, Improving Lives.’”
About ANI
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit www.anipharmaceuticals.com.
Forward-Looking Statements
To the extent any statements made in this release deal with information that is not historical, these are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, those relating to the commercialization and potential sales of the product and any additional product launches from the Company’s generic pipeline, 2025 guidance, other statements that are not historical in nature, particularly those that utilize terminology such as “anticipates,” “will,” “expects,” “plans,” “potential,” “future,” “believes,” “intends,” “continue,” other words of similar meaning, derivations of such words and the use of future dates.
Uncertainties and risks may cause the Company’s actual results to be materially different than those expressed in or implied by such forward-looking statements. Uncertainties and risks include, but are not limited to: the ability of our approved products, including Cortrophin Gel, ILUVIEN and YUTIQ, to achieve commercialization at levels of market acceptance that will continue to allow us to achieve profitability; our ability to complete or achieve any, or all of the intended benefits of acquisitions and investments, including the acquisition of Alimera, in a timely manner or at all; the limitation of our cash flow as a result of the indebtedness and liabilities incurred from the recent acquisition of Alimera; the risks that our acquisitions and investments, including the recent acquisition of Alimera, could disrupt our business and harm our financial position and operating results; delays and disruptions in production of our approved products, increased costs and potential loss of revenues if we need to change suppliers due to the limited number of suppliers for our raw materials, active pharmaceutical ingredients, expedients, and other materials; delays and disruptions in production of our approved products as a result of our reliance on single source third party contract manufacturing supply for certain of our key products, including Cortrophin Gel, ILUVIEN and YUTIQ; delays or failure in obtaining and maintaining approvals by the FDA of the products we sell; changes in policy or actions that may be taken by the FDA, United States Drug Enforcement Administration and other regulatory agencies, and the focus of the current U.S. presidential administration, including among other things, drug recalls, regulatory approvals, facility inspections and potential enforcement actions; risks that we may face with respect to importing raw materials and delays in delivery of raw materials and other ingredients and supplies necessary for the manufacture of our products from both domestic and overseas sources due to supply chain disruptions or for any other reason; the ability of our manufacturing partners to meet our product demands and timelines; the impact of changes or fluctuations in exchange rates; our ability to develop, license or acquire, and commercialize new products; our obligations in agreements under which we license, develop or commercialize rights to products or technology from third parties and our ability to maintain such licenses; the level of competition we face and the legal, regulatory and/or legislative strategies employed by our competitors to prevent or delay competition from generic alternatives to branded products; our ability to protect our intellectual property rights; the impact of legislative or regulatory reform on the pricing for pharmaceutical products; the impact of any litigation to which we are, or may become, a party; our ability, and that of our suppliers, development partners, and manufacturing partners, to comply with laws, regulations and standards that govern or affect the pharmaceutical and biotechnology industries; our ability to maintain the services of our key executives and other personnel; and general business and economic conditions, such as inflationary pressures, geopolitical conditions including but not limited to the conflict between Russia and the Ukraine, the conflict in the Middle East, conflicts related to the attacks on cargo ships in the Red Sea, and the effects and duration of outbreaks of public health emergencies, and other risks and uncertainties that are described in ANI’s Annual Report on Form 10-K, quarterly reports on Form 10-Q, and other periodic reports filed with the Securities and Exchange Commission.
More detailed information on these and additional factors that could affect the Company’s actual results are described in the Company’s filings with the Securities and Exchange Commission (SEC), including its most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as other filings with the SEC. All forward-looking statements in this news release speak only as of the date of this news release and are based on the Company’s current beliefs, assumptions, and expectations. The Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Investor Contact Lisa M. Wilson, In-Site Communications, Inc.
212-452-2793
lwilson@insitecony.com
SOURCE: ANI Pharmaceuticals, Inc.
FAQ
How much did ANI Pharmaceuticals pay to buy out the ILUVIEN and YUTIQ royalty obligation?
When does the royalty buyout for ANIP's retina products take effect?
What was the royalty rate ANIP was paying for ILUVIEN and YUTIQ before the buyout?
How did ANI Pharmaceuticals (ANIP) fund the royalty buyout payment?
What products are affected by ANIP's royalty buyout agreement with SWK Funding?
